Cargando…

Clinical utility of exemestane in the treatment of breast cancer

Breast cancer is the most prevalent cancer in women, causing a significant mortality worldwide. Different endocrine strategies are available for the treatment of hormone-sensitive breast cancer, including antiestrogen tamoxifen and fulvestrant, as well as third-generation aromatase inhibitors (AIs),...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zucchini, Giorgia, Geuna, Elena, Milani, Andrea, Aversa, Caterina, Martinello, Rossella, Montemurro, Filippo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2015
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4455847/ https://www.ncbi.nlm.nih.gov/pubmed/26064072 http://dx.doi.org/10.2147/IJWH.S69475

Ejemplares similares

Treatment with Beta-Blockers and ACE-Inhibitors in Breast Cancer Patients Receiving Adjuvant Trastuzumab-Based Therapy and Developing Mild Cardiac Toxicity: A Prospective Study
por: Geuna, Elena, et al.
Publicado: (2020)

Exemestane in the Adjuvant Treatment of Breast Cancer in Postmenopausal Women
por: Kittaneh, Muaiad, et al.
Publicado: (2011)

The Clinical Efficacy and Safety of Neratinib in Combination with Capecitabine for the Treatment of Adult Patients with Advanced or Metastatic HER2-Positive Breast Cancer
por: Chilà, Giovanna, et al.
Publicado: (2021)

Apoptosis and Autophagy in Breast Cancer Cells following Exemestane Treatment
por: Amaral, Cristina, et al.
Publicado: (2012)

Long-term efficacy and safety of exemestane in the treatment of breast cancer
por: Walker, GA, et al.
Publicado: (2013)

Exemestane in early breast cancer: a review
por: Untch, Michael, et al.
Publicado: (2008)

Self‐evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study
por: Galizia, Danilo, et al.
Publicado: (2018)

A review of the use of exemestane in early breast cancer
por: Robinson, Andrew
Publicado: (2009)

Cost-effectiveness analysis review of exemestane in the treatment of primary and advanced breast cancer
por: Hashemi-Meshkini, Amir, et al.
Publicado: (2013)

Quality of life in relation to tamoxifen or exemestane treatment in postmenopausal breast cancer patients: a Tamoxifen Exemestane Adjuvant Multinational (TEAM) Trial side study
por: van Nes, J. G. H., et al.
Publicado: (2012)

Trastuzumab with either docetaxel or vinorelbine as first-line treatment for patients with HER2-positive advanced breast cancer: a retrospective comparison
por: Redana, Stefania, et al.
Publicado: (2010)

Mutational Profile of Metastatic Breast Cancer Tissue in Patients Treated with Exemestane Plus Everolimus
por: Omarini, Claudia, et al.
Publicado: (2018)

Subepithelial Corneal Deposits Associated with Exemestane
por: Amireskandari, Annahita, et al.
Publicado: (2020)

Neoadjuvant exemestane or exemestane plus docetaxel and cyclophosphamide tailored by clinicopathological response to 12 weeks' exemestane exposure in patients with estrogen receptor‐positive breast cancer: A multicenter, open‐label, phase II study
por: Sato, Nobuaki, et al.
Publicado: (2019)

Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2
por: Noguchi, Shinzaburo, et al.
Publicado: (2013)

Uptake of exemestane chemoprevention in postmenopausal women at increased risk for breast cancer
por: Aktas, Bilge, et al.
Publicado: (2016)

Methylome Variation Predicts Exemestane Resistance in Advanced ER(+) Breast Cancer
por: Liu, Xiao-ran, et al.
Publicado: (2020)

Methotrexate-Lactoferrin Targeted Exemestane Cubosomes for Synergistic Breast Cancer Therapy
por: Mokhtar, Sarah, et al.
Publicado: (2022)

Effects of tamoxifen and exemestane on cognitive function in postmenopausal patients with breast cancer
por: Lee Meeuw Kjoe, Philippe R, et al.
Publicado: (2023)

Antiproliferative effect of exemestane in lung cancer cells
por: Koutras, Angelos, et al.
Publicado: (2009)

Everolimus Plus Exemestane for the Treatment of Advanced Breast Cancer: A Review of Subanalyses from BOLERO-2()
por: Hortobagyi, Gabriel N.
Publicado: (2015)

Underuse of Anthracyclines in Women with HER-2(+) Advanced Breast Cancer
por: Montemurro, Filippo, et al.
Publicado: (2010)

Early Changes of the Standardized Uptake Values (SUV(max)) Predict the Efficacy of Everolimus-Exemestane in Patients with Hormone Receptor-Positive Metastatic Breast Cancer
por: Sirico, Marianna, et al.
Publicado: (2020)

Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early‐Stage Breast Cancer
por: Cairns, Junmei, et al.
Publicado: (2021)

Ruxolitinib and exemestane for estrogen receptor positive, aromatase inhibitor resistant advanced breast cancer
por: Makhlin, Igor, et al.
Publicado: (2022)

Comparison of a histone deacetylase inhibitor plus exemestane with exemestane alone in hormone receptor-positive advanced breast cancer that progressed on prior endocrine therapy: A meta-analysis
por: Xu, Liang, et al.
Publicado: (2022)

Exemestane as primary treatment of oestrogen receptor-positive breast cancer in postmenopausal women: a phase II trial
por: Barnadas, A, et al.
Publicado: (2009)

Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)—PathIES
por: Szijgyarto, Zsolt, et al.
Publicado: (2019)

Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer
por: Iaffaioli, R V, et al.
Publicado: (2005)

Phase II study of sequential hormonal therapy with anastrozole/exemestane in advanced and metastatic breast cancer
por: Iaffaioli, R V, et al.
Publicado: (2005)

Efficacy of Exemestane in Korean Patients with Metastatic Breast Cancer after Failure of Nonsteroidal Aromatase Inhibitors
por: Lee, June Koo, et al.
Publicado: (2013)

Abiraterone acetate, exemestane or the combination in postmenopausal patients with estrogen receptor-positive metastatic breast cancer(†)
por: O'Shaughnessy, J., et al.
Publicado: (2016)

Everolimus and exemestane in long survival hormone receptor positive male breast cancer: case report
por: Ballatore, Z., et al.
Publicado: (2016)

Statin use in patients with hormone receptor‐positive metastatic breast cancer treated with everolimus and exemestane
por: Lee, Kyoungmin, et al.
Publicado: (2022)

Preclinical evaluation of exemestane as a novel chemotherapy for gastric cancer
por: Yang, Juan‐Cheng, et al.
Publicado: (2019)

Inhibition of the Aromatase Enzyme by Exemestane Cysteine Conjugates
por: Teslenko, Irina, et al.
Publicado: (2022)

Endocrinological and clinical evaluation of exemestane, a new steroidal aromatase inhibitor.
por: Zilembo, N., et al.
Publicado: (1995)

Fasting glucose and body mass index as predictors of activity in breast cancer patients treated with everolimus-exemestane: The EverExt study
por: Pizzuti, Laura, et al.
Publicado: (2017)

Influence of Glutathione-S-Transferase A1*B Allele on the Metabolism of the Aromatase Inhibitor, Exemestane, in Human Liver Cytosols and in Patients Treated With Exemestane
por: Teslenko, Irina, et al.
Publicado: (2022)

Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in post-menopausal patients with breast cancer
por: Hertz, Daniel L., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_kdfmpuaaokn15gihgf42m8v164